Cytokinetics, Incorporated (CYTK)

Cytokinetics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-589.53	-526.24	-388.96	-215.31
Depreciation & Amortization	9.53	11.89	5.81	2.28
Loss (Gain) From Sale of Assets	0.05	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	2.84
Loss (Gain) From Sale of Investments	-0.02	0.04	0.11	-
Stock-Based Compensation	97.84	72.07	47.85	26.83
Other Operating Activities	50.58	24.83	60.37	32.38
Change in Accounts Receivable	-15.37	-1.14	56.67	-47.4
Change in Accounts Payable	-4.48	-3.48	4.52	1.06
Change in Unearned Revenue	52.37	-	-87	-
Change in Other Net Operating Assets	3.14	7.71	1.1	54.8
Operating Cash Flow	-395.89	-414.33	-299.52	-142.52
Capital Expenditures	-3.91	-1.42	-11.34	-48.87
Investment in Securities	-549.19	240.67	-250.8	-98.91
Investing Cash Flow	-553.1	239.25	-262.13	-147.78
Long-Term Debt Issued	-	-	523.59	-
Long-Term Debt Repaid	-9.62	-0.86	-188.93	-
Net Debt Issued (Repaid)	-9.62	-0.86	334.66	-
Issuance of Common Stock	759.86	182.69	17.54	324.85
Repurchase of Common Stock	-19.63	-10.52	-9.6	-4.87
Other Financing Activities	200	50	173.56	-
Financing Cash Flow	930.61	221.32	516.17	319.98
Foreign Exchange Rate Adjustments	0.21	-0.02	-	-
Net Cash Flow	-18.17	46.22	-45.48	29.68
Free Cash Flow	-399.8	-415.75	-310.85	-191.39
Free Cash Flow Margin	-2164.10%	-5521.23%	-328.64%	-271.76%
Free Cash Flow Per Share	-3.57	-4.31	-3.46	-2.49
Cash Interest Paid	25.97	10.3	15.17	9.18
Levered Free Cash Flow	-241.49	-260.37	-127.01	-179.83
Unlevered Free Cash Flow	-187.42	-224.33	-95.04	-161.5
Change in Working Capital	35.66	3.09	-24.7	8.46

Updated Feb 24, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q